AZNA Stock Overview
A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 5/6 |
AstraZeneca PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£72.00 |
| 52 Week High | UK£72.00 |
| 52 Week Low | UK£57.50 |
| Beta | 0.16 |
| 1 Month Change | 10.77% |
| 3 Month Change | 17.07% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 25.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| AZNA | AT Pharmaceuticals | AT Market | |
|---|---|---|---|
| 7D | 0% | 0.06% | 1.6% |
| 1Y | n/a | 10.5% | 10.3% |
Return vs Industry: Insufficient data to determine how AZNA performed against the Austrian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how AZNA performed against the Austrian Market.
Price Volatility
| AZNA volatility | |
|---|---|
| AZNA Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in AT Market | 5.4% |
| 10% least volatile stocks in AT Market | 1.6% |
Stable Share Price: AZNA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine AZNA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 89,900 | Pascal Soriot | www.astrazeneca.com |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease.
AstraZeneca PLC Fundamentals Summary
| AZNA fundamental statistics | |
|---|---|
| Market cap | €219.41b |
| Earnings (TTM) | €5.83b |
| Revenue (TTM) | €43.81b |
37.7x
P/E Ratio5.0x
P/S RatioIs AZNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AZNA income statement (TTM) | |
|---|---|
| Revenue | US$47.61b |
| Cost of Revenue | US$8.33b |
| Gross Profit | US$39.28b |
| Other Expenses | US$32.95b |
| Earnings | US$6.33b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 25, 2024
| Earnings per share (EPS) | 4.08 |
| Gross Margin | 82.50% |
| Net Profit Margin | 13.30% |
| Debt/Equity Ratio | 89.2% |
How did AZNA perform over the long term?
See historical performance and comparison